Preclinical and promising: APVO442, bispecific antibody for prostate cancer

[Maxone73]

Aptevo Therapeutics has developed a new bispecific antibody called APVO442 for targeted prostate cancer treatment.

This antibody is the first to be created using Aptevo's ADAPTIR-FLEX platform, a technology designed to engineer antibodies for challenging cancers. APVO442 works by binding to PSMA, found on prostate cancer cells, and CD3, found on T cells. This brings T cells close to cancer cells, enhancing targeted tumor cell killing.

Preclinical studies show APVO442 effectively targets solid tumors, avoids binding to immune cells in the bloodstream, and enhances the immune response against tumor cells. APVO442 also has potential for use in combination therapy with other cancer treatments.

prostatewarriors.com/2024/1...